Lenograstim: Clinical Trials

10 trials of Lenograstim, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 unknown, 1 terminated. 10 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Completed 7, Unknown 2, Terminated 1
Phase 23Completed 2, Terminated 1

Follow Lenograstim: new trials by email Literature Review of Lenograstim trials Research Report on Lenograstim

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF) - Prostate Cancer Metastatic
Phase 3CompletedAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie1962017-05-052022-05-12
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Azacitadine, Fludarabine, Cytarabine - Acute Myeloid Leukemia
Phase 3CompletedPETHEMA Foundation2892014-10-012020-04-06
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)
Melphalan, Lenograstim - Castrate Resistant Prostate Cancer
Phase 2 / Phase 3TerminatedBarts & The London NHS Trust292013-01-012023-04-19
Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction
Lenograstim (GRANOCYTE)=GCSF, Sitagliptin (Januvia), Sodium Chloride (NaCl) 0.9 % - Acute Myocardial Infarction
Phase 2 / Phase 3CompletedLudwig-Maximilians - University of Munich1742008-03-012022-08-25
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
Docetaxel, Epirubicin, Cyclophosphamide - Breast Cancer
Phase 3CompletedHellenic Oncology Research Group6502007-10-012014-05-14
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
Rituximab, Ciclofosfamide, Doxorubicina - Diffuse Large B-Cell Lymphoma, IPI≥2
Phase 3UnknownFondazione Italiana Linfomi - ETS3992006-01-012011-02-15
Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma
filgrastim, lenograstim - G-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim
Phase 3UnknownUniversity of Pisa1802004-12-012009-07-03
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Docetaxel, Trastuzumab, Epirubicin - Breast Cancer
Phase 3CompletedHellenic Oncology Research Group4892004-10-012015-03-04
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Docetaxel, Paclitaxel, Epirubicin - Breast Cancer
Phase 3CompletedHellenic Oncology Research Group4782004-08-012008-01-21
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy
lenograstim - Hodgkin's Disease, Non-Hodgkin Lymphomas
Phase 2 / Phase 3CompletedWiSP Wissenschaftlicher Service Pharma GmbH1692003-05-012010-03-11

Conditions studied

Breast Neoplasms (3)  ·  Multiple Myeloma (2)  ·  Hodgkin Disease (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Myocardial Infarction (1)

Sponsors

Hellenic Oncology Research Group (3)  ·  Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (1)  ·  Barts & The London NHS Trust (1)  ·  Fondazione Italiana Linfomi - ETS (1)  ·  Ludwig-Maximilians - University of Munich (1)  ·  PETHEMA Foundation (1)  ·  University of Pisa (1)  ·  WiSP Wissenschaftlicher Service Pharma GmbH (1)

Countries

Greece (3)  ·  Germany (2)  ·  France (1)  ·  Italy (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Dimitris Mavrudis, MD (3)  ·  Jonathan Shamash, MD FRCP (1)  ·  Pau Montesinos, Dr (1)  ·  Umberto Vitolo, MD (1)  ·  Wolfgang M Franz, Prof. Dr. (1)

Results publications

PMID 21163927, PMID 26709136, PMID 27502729, PMID 28668386, PMID 32817282, PMID 33463373, PMID 34070172, PMID 37883073, PMID 42020286